COVID-19 mRNA vaccines
Copyright policy )COVID-19 mRNA vaccines
The ongoing COVID-19 pandemic and its unprecedented global societal and economic disruptive impact highlight the urgent need for safe and effective vaccines. Taking substantial advantages of versatility and rapid development, two mRNA vaccines against COVID-19 have completed late-stage clinical assessment at an unprecedented speed and reported positive results. In this review, we outline keynotes in mRNA vaccine development, discuss recently published data on COVID-19 mRNA vaccine candidates, focusing on those in clinical trials and analyze future potential challenges.
- University of Chinese Academy of Sciences China (People's Republic of)
- Institute of Microbiology China (People's Republic of)
- Chinese Academy of Sciences China (People's Republic of)
Vaccines, Synthetic, Binding Sites, COVID-19 Vaccines, SARS-CoV-2, COVID-19, Review, Viral Proteins, Drug Development, Humans, RNA, Messenger, mRNA Vaccines, Pandemics
Vaccines, Synthetic, Binding Sites, COVID-19 Vaccines, SARS-CoV-2, COVID-19, Review, Viral Proteins, Drug Development, Humans, RNA, Messenger, mRNA Vaccines, Pandemics
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).79 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!